이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era

A Prospective Cohort Study of Radiotherapy Target Volume Delineation Patterns in Locally Advanced Esophageal Cancer in the Immunotherapy Era

This prospective observational cohort study will evaluate different radiotherapy target volume delineation patterns in patients with locally advanced esophageal squamous cell carcinoma receiving radiotherapy combined with immunotherapy.

In routine clinical practice, physicians may use different margins around the primary tumor and different approaches to regional lymph node irradiation. The study will not assign participants to a specific radiotherapy strategy. Instead, participants will receive treatment according to routine clinical practice, and the actual radiotherapy plans will be recorded and analyzed.

The study will compare locoregional tumor control, recurrence patterns, survival, treatment-related toxicity, lymphocyte reduction, and completion of immunotherapy among patients receiving different target volume strategies. The main objective is to evaluate 2-year locoregional recurrence-free survival and to identify radiotherapy approaches that may achieve effective tumor control while reducing unnecessary radiation exposure and treatment-related toxicity.

연구 개요

상세 설명

This is a prospective, non-interventional observational cohort study of patients with locally advanced esophageal squamous cell carcinoma treated with radiotherapy in combination with immunotherapy in routine clinical practice. Treatment decisions, including radiotherapy target volume delineation and systemic therapy, will be made by the treating physicians according to the patient's clinical condition and routine clinical practice and will not be assigned by the study protocol.

Eligible participants will be prospectively followed, and clinical, imaging, pathological, radiotherapy planning, systemic treatment, laboratory, toxicity, and follow-up data will be collected. Participants will be classified according to the radiotherapy strategy actually received, particularly the longitudinal gross tumor volume-to-clinical target volume (GTV-CTV) margin and the extent of regional lymph node irradiation, including involved-field irradiation and approaches incorporating partial elective nodal irradiation.

The primary objective is to compare 2-year locoregional recurrence-free survival among patients receiving different target volume delineation strategies. Additional outcomes include marginal and regional recurrence patterns, overall survival, treatment-related toxicity, lymphocyte reduction, immunotherapy completion, and other treatment outcomes.

The study will also evaluate whether clinical and biological factors, including tumor location and length, T and N stage, lymph node burden, PET/CT metabolic parameters, PD-L1 combined positive score, circulating tumor DNA status, and radiotherapy dosimetric parameters, are associated with the effectiveness and safety of different target volume strategies. Target trial emulation, propensity score methods, and multivariable models will be used where appropriate to reduce confounding and to explore factors associated with recurrence and toxicity.

연구 유형

관찰

등록 (추정된)

500

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100021
        • 모병
        • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
        • 연락하다:
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Patients with locally advanced esophageal squamous cell carcinoma who are treated at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College and are considered suitable for definitive or preoperative radiotherapy combined with immunotherapy will be prospectively and consecutively enrolled. Treatment decisions will be made according to routine clinical practice. Participants will be followed to evaluate the association between actual radiotherapy target volume delineation patterns and locoregional control, recurrence, survival, toxicity, lymphocyte reduction, and immunotherapy completion.

설명

Inclusion Criteria:

  1. Age 18 to 80 years, regardless of sex.
  2. Histologically confirmed esophageal squamous cell carcinoma.
  3. Clinical stage cT2-4aN0-3M0, or considered by a multidisciplinary team to be suitable for definitive immunotherapy combined with radiotherapy or preoperative immunotherapy combined with radiotherapy.
  4. Planned to receive one of the following modern precision radiotherapy techniques: IMRT, VMAT, TOMO, proton therapy, or heavy-ion radiotherapy.
  5. Contrast-enhanced CT completed before radiotherapy; endoscopy, EUS, PET/CT, or MRI is recommended when clinically appropriate to assist target volume delineation.
  6. ECOG performance status of 0-2.
  7. Expected survival of at least 6 months.
  8. Able to understand the study and provide written informed consent.

Exclusion Criteria:

  1. Presence of distant metastasis or malignant pleural or peritoneal effusion.
  2. Previous thoracic radiotherapy that may affect the current target volume design or dose constraints.
  3. Pre-existing esophagotracheal fistula, esophagoaortic fistula, or a high risk of perforation considered unsuitable for radiotherapy.
  4. Active interstitial lung disease, severe infection, or uncontrolled autoimmune disease considered unsuitable for immunotherapy.
  5. Severe missing data that prevent determination of the actual CTV margin, lymph node irradiation extent, or major study outcomes.
  6. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Locally Advanced ESCC Cohort

Patients with locally advanced esophageal squamous cell carcinoma who receive radiotherapy combined with immunotherapy in routine clinical practice will be prospectively enrolled. Treatment and radiotherapy target volume delineation will not be assigned by the study protocol. Patients will be characterized according to the radiotherapy strategy actually received, including the longitudinal GTV-CTV margin and the extent of regional lymph node irradiation. Clinical, imaging, pathological, dosimetric, treatment, toxicity, and follow-up data will be prospectively collected to evaluate locoregional control, recurrence patterns, survival, lymphocyte reduction, and immunotherapy completion.

The longitudinal margin from the gross tumor volume (GTV) to the clinical target volume (CTV) actually used in routine clinical practice will be recorded and analyzed. The study protocol does not assign a specific margin.

The extent of regional lymph node irradiation actually used in routine clinical practice, including involved-field irradiation and approaches incorporating partial elective nodal irradiation, will be recorded and analyzed. The study protocol does not assign a specific nodal irradiation strategy.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
2-Year Locoregional Recurrence-Free Survival
기간: Up to 2 years from the start of radiotherapy

Locoregional recurrence-free survival (LRFS) is defined as the time from the start of radiotherapy to locoregional tumor recurrence, death from any cause, loss to follow-up, or the last follow-up, according to the study protocol. The 2-year LRFS rate will be compared among patients receiving different radiotherapy target volume delineation strategies.

Up to 2 years from the start of radiotherapy

2차 결과 측정

결과 측정
측정값 설명
기간
2-Year Overall Survival
기간: Up to 2 years from radiotherapy

Overall survival (OS) is defined as the time from the start of radiotherapy to death from any cause, loss to follow-up, or the last follow-up. The 2-year overall survival rate will be evaluated among participants receiving different radiotherapy target volume strategies.

Up to 2 years from radiotherapy
Marginal and Regional Recurrence Rate
기간: Up to 2 years from radiotherapy

The proportion of participants who develop marginal recurrence or regional lymph node recurrence during follow-up. Recurrence will be determined by pathological or cytological confirmation when available, or by serial imaging showing a new or progressively enlarging lesion consistent with recurrence.

Up to 2 years from radiotherapy
Incidence of Grade 3 or Higher Treatment-Related Toxicity
기간: From treatment initiation through 2-year follow-up

The incidence of grade 3 or higher treatment-related adverse events will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Toxicities of interest include radiotherapy-related and systemic treatment-related adverse events.

From treatment initiation through 2-year follow-up

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 8월 23일

기본 완료 (추정된)

2034년 7월 30일

연구 완료 (추정된)

2036년 8월 31일

연구 등록 날짜

최초 제출

2026년 9월 29일

QC 기준을 충족하는 최초 제출

2026년 9월 29일

처음 게시됨 (실제)

2026년 10월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 29일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data will not be shared with external researchers because the current study protocol does not include a plan for external sharing of participant-level data. Study data will be stored with controlled access and will be available only to authorized study personnel. Study results will be reported in aggregate form to protect participant privacy and confidentiality.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다